GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shijiazhuang Yiling Pharmaceutical Co Ltd (SZSE:002603) » Definitions » Cash Conversion Cycle

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Cash Conversion Cycle : 48.85 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Shijiazhuang Yiling Pharmaceutical Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Shijiazhuang Yiling Pharmaceutical Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 89.79.
Shijiazhuang Yiling Pharmaceutical Co's Days Inventory for the three months ended in Mar. 2024 was 166.22.
Shijiazhuang Yiling Pharmaceutical Co's Days Payable for the three months ended in Mar. 2024 was 207.16.
Therefore, Shijiazhuang Yiling Pharmaceutical Co's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 48.85.


Shijiazhuang Yiling Pharmaceutical Co Cash Conversion Cycle Historical Data

The historical data trend for Shijiazhuang Yiling Pharmaceutical Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shijiazhuang Yiling Pharmaceutical Co Cash Conversion Cycle Chart

Shijiazhuang Yiling Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 184.53 111.53 71.47 49.11 55.34

Shijiazhuang Yiling Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.32 55.19 107.24 116.47 48.85

Competitive Comparison of Shijiazhuang Yiling Pharmaceutical Co's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Shijiazhuang Yiling Pharmaceutical Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shijiazhuang Yiling Pharmaceutical Co's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shijiazhuang Yiling Pharmaceutical Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Shijiazhuang Yiling Pharmaceutical Co's Cash Conversion Cycle falls into.



Shijiazhuang Yiling Pharmaceutical Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Shijiazhuang Yiling Pharmaceutical Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=73.01+185.51-203.18
=55.34

Shijiazhuang Yiling Pharmaceutical Co's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=89.79+166.22-207.16
=48.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shijiazhuang Yiling Pharmaceutical Co  (SZSE:002603) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Shijiazhuang Yiling Pharmaceutical Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Shijiazhuang Yiling Pharmaceutical Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Business Description

Traded in Other Exchanges
N/A
Address
No. 7 Tianfu street, Biology and medicine industrial base, Huangcun town, Daxing district, Beijing, CHN
Shijiazhuang Yiling Pharmaceutical Co Ltd is a China-based company engages in the pharmaceutical manufacturing. The company is principally engaged in the research, development, manufacturing, and sales of traditional Chinese pharmaceutical products, especially in the fields of cardiovascular and cerebrovascular diseases, respiratory diseases, tumor, diabetes and related complications. Its products include innovative drug series, chemical drugs, Chinese medicine series, and health products.
Executives
Zhang Qiu Lian Directors, executives
Han Yue Zhi Executives
Zhao Shao Hua Executives
Wang Wei Executives
Gao Xue Dong Supervisors
Wu Yi Ling Director
Gao Xiu Qiang Executives
Wu Xiang Jun Directors, executives
Guo Shuang Geng Director
Wang Hua Securities Affairs Representative
Dai Feng Xiang Directors, executives
Liu Gen Wu Supervisors
Wang Wei Ping Directors, executives
Xu Wei Dong Director
Wu Rui Directors, executives

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Headlines

No Headlines